Literature DB >> 26261870

CD55, CD59, factor H and factor H-like 1 gene expression analysis in tumors of the ovary and corpus uteri origin.

L Kapka-Skrzypczak1, E Wolinska2, G Szparecki3, G M Wilczynski4, M Czajka5, M Skrzypczak6.   

Abstract

The expression level of complement regulators in ovarian and corpus uteri tumors was not fully established so far. In current manuscript we performed gene expression analysis by the real-time PCR approach to investigate both membrane bound - CD55 and CD59 and fluid phase - factor H and factor H-like 1 complement regulators. We found increased CD55 expression in corpus uteri tumors when compared to control tissues, whereas in ovarian cancer CD55 expression was lower than in control sections. Additionally we found CD59 expression to be more prominent in ovarian cancer than in corpus uteri tumor samples. We observed also the strong positive correlation between the level of expression of the whole group of regulators, which was particularly significant between the expression of factor H and factor H- like 1. In conclusion we present novel results which implicates different role of particular complement inhibitors in the regulation of the complement system in two cancer types examined. Strong positive correlation between examined proteins implicates similar pattern of the regulation which should be taken into consideration with regards to the possible immunotherapy applied as adjuvant therapeutic approach in these two indications. The inhibition of complement regulation may serve as a strategy to potentiate the efficacy of such treatment.
Copyright © 2015 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CD55; CD59; Factor H; Factor H-like 1; Gynecological cancer

Mesh:

Substances:

Year:  2015        PMID: 26261870     DOI: 10.1016/j.imlet.2015.06.017

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  6 in total

Review 1.  Complement in cancer: untangling an intricate relationship.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; Alberto Mantovani; John D Lambris
Journal:  Nat Rev Immunol       Date:  2017-09-18       Impact factor: 53.106

Review 2.  Deciphering the Intricate Roles of Radiation Therapy and Complement Activation in Cancer.

Authors:  Jacob Gadwa; Sana D Karam
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-07-03       Impact factor: 7.038

Review 3.  GPI-AP: Unraveling a New Class of Malignancy Mediators and Potential Immunotherapy Targets.

Authors:  Nada H Hussein; Nada S Amin; Hend M El Tayebi
Journal:  Front Oncol       Date:  2020-12-04       Impact factor: 6.244

Review 4.  Context-dependent roles of complement in cancer.

Authors:  Lubka T Roumenina; Marie V Daugan; Florent Petitprez; Catherine Sautès-Fridman; Wolf Herman Fridman
Journal:  Nat Rev Cancer       Date:  2019-10-30       Impact factor: 60.716

5.  IL‑6 and IL‑8 enhance factor H binding to the cell membranes.

Authors:  Sylwia Popek; Lucyna Kapka-Skrzypczak; Krzysztof Sawicki; Ewa Wolińska; Maciej Skrzypczak; Magdalena Czajka
Journal:  Mol Med Rep       Date:  2016-03-18       Impact factor: 2.952

Review 6.  The tumour microenvironment links complement system dysregulation and hypoxic signalling.

Authors:  Monica M Olcina; Ryan K Kim; Stavros Melemenidis; Edward E Graves; Amato J Giaccia
Journal:  Br J Radiol       Date:  2018-05-15       Impact factor: 3.039

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.